- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03900026
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)
A Randomized Trial of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery (NEWTON-CABG)
Study Overview
Status
Intervention / Treatment
Detailed Description
Coronary artery bypass graft (CABG) surgery is a procedure in which an artery or vein from the body is grafted to a critically narrowed coronary artery to restore flow of oxygenated blood to the heart. Statins are frequently prescribed after CABG surgery in order to lower LDL cholesterol levels and reduce the chances of coronary artery obstruction recurring. Despite this preventive measure, new vein grafts do end up becoming blocked in a significant proportion of patients. Evolocumab (Repatha®) is a recently approved medication that has been shown to effectively lower LDL cholesterol levels in the blood.
NEWTON-CABG is an investigator-initiated multicenter, double-blind, randomized, placebo-controlled, parallel group study of evolocumab [140mg administered subcutaneously (SC) every two weeks (Q2W)] added to statin therapy for 24 months postoperatively in a broad population of patients undergoing CABG surgery. Eligible subjects will be randomized to receive evolocumab or placebo within 21 days of index CABG. Prior to randomization, post-operative patients will be on moderate or high intensity statin therapy (atorvastatin 40-80mg, rosuvastatin 20-40mg or simvastatin 40mg daily unless another statin/dose or non-statin alternative is clinically justified). A CTAngiogram will be conducted at 24 months following CABG. Routine study visits will be done 3, 6, 12, 18 and 24 months post-surgery.
This study is supported by Amgen Inc.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Danusha Nandamalavan
- Phone Number: 77038 416-864-6060
- Email: NandamalavaD@smh.ca
Study Locations
-
-
-
Calgary, Canada
- Recruiting
- Foothills Medical Centre
-
Contact:
- Karen Maier
- Email: Karen.Maier@albertahealthservices.ca
-
Principal Investigator:
- Alex Gregory
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R8
- Recruiting
- University of Alberta
-
Contact:
- Maliha Muneer
- Phone Number: 780-407-8614
- Email: muneer@ualberta.ca
-
Principal Investigator:
- Andrew Shaw
-
-
Ontario
-
Hamilton, Ontario, Canada
- Recruiting
- Hamilton Health Sciences
-
Contact:
- Courtney Mullen
- Phone Number: 44342 905.521.2100
- Email: Courtney.Mullen@phri.ca
-
Principal Investigator:
- Richard Whitlock
-
Kingston, Ontario, Canada, K7L 2V7
- Recruiting
- Kingston Health Sciences Centre
-
Contact:
- Deborah DuMerton
- Phone Number: 3224 613-549-6666
- Email: Deborah.DuMerton@kingstonhsc.ca
-
Toronto, Ontario, Canada, M5B 1W8
- Recruiting
- St. Michael's Hospital
-
Contact:
- Shira Brodutch
- Phone Number: 49419 416-864-6060
- Email: Shira.Brodutch@unityhealth.to
-
-
Quebec
-
Québec, Quebec, Canada
- Recruiting
- Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
-
Contact:
- Hugo Tremblay
- Phone Number: 3797 418-656-8711
- Email: hugo.tremblay@criucpq.ulaval.ca
-
Principal Investigator:
- Francois Dagenais
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale University School of Medicine
-
Contact:
- Kimberly Kunze
- Phone Number: 203-737-2150
- Email: kim.kunze@yale.edu
-
Principal Investigator:
- Umer Darr
-
-
Florida
-
Jacksonville, Florida, United States, 32216
- Recruiting
- Jacksonville Center for Clinical Research
-
Contact:
- Heather Burns
- Phone Number: 904-576-0166
- Email: heathburns@encoredocs.com
-
Principal Investigator:
- Michael Koren
-
-
Maine
-
Portland, Maine, United States, 04102
- Recruiting
- Maine Medical Center
-
Contact:
- Betsey Gallant
- Email: WIGHTA@mmc.org
-
Contact:
- Phone Number: 207-662-1489
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria - To be considered eligible for participation in this study, a participant must satisfy each of the following criteria:
- Age ≥ 18 years
- Scheduled to undergo coronary artery bypass graft (CABG) surgery (with or without cardiopulmonary bypass (CPB); with or without single valve repair/replacement)
- CABG procedure included/planned to include at least two saphenous vein grafts
- CABG procedure occurred within the past 21 days, or is planned within the next 60 days
- On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily, rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin or non-statin therapy is clinically justified
Exclusion Criteria - A participant will be ineligible for participation in this study if he or she satisfies any one or more of the following criteria:
- Patients in whom additional lowering of LDL-C with evolocumab is deemed to be clinically inappropriate
- Allergy to contrast dye
- Known severe hepatic impairment (Childs-Pugh, Class C).
- Known renal disease with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
- Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow)
- Use of cholesterylester transfer protein (CETP) inhibition treatment within 12 months prior to randomization.
- Current, prior within past year, or known planned use of PCSK9 inhibition treatment
- Severe cardiovascular or concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 2 years
- Major active infection, or major hematologic, renal, respiratory, metabolic, gastrointestinal or endocrine dysfunction
- Women who are pregnant or breastfeeding
- Women of child bearing potential who are unwilling to use proper family planning or birth control methods to avoid pregnancy. Women are considered post-menopausal and not of childbearing potential after 12 months of natural (spontaneous) amenorrhea or have had a surgical procedure such as hysterectomy which makes pregnancy impossible.
- Known intolerance or allergy to evolocumab or other PCSK9 inhibitors.
- Currently taking simvastatin >40mg/day, niacin or bile acid sequestrants
- Known latex allergy
- Inability to comply with protocol-required study visits or procedures, including administration of study drug
- Known history of cancer within the past 5 years (except for carcinoma in-situ of the cervix, stage 1 prostate cancer or adequately treated non-melanoma carcinomas of the skin)
- Participation in another investigational device or drug study which is likely to affect the primary outcome, within 30 days of planned initiation of study drug
- NYHA class IV
- Pacemaker or other implantable device implanted within 30 days prior to screening
Additional postoperative exclusion criteria:
- Received only <2 vein grafts
- Major peri-operative complications following CABG surgery (e.g. stroke, MI, renal failure requiring dialysis, or postoperative ICU stay > 5 days) prior to randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Treatment
Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
|
Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
Other Names:
|
Experimental: Evolocumab Treatment
Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
|
REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Saphenous vein graft disease rate (VGDR)
Time Frame: 24 months post CABG
|
Saphenous vein graft disease rate (VGDR) is defined as the proportion of vein grafts with significant stenosis or total occlusion (≥50%) on 64-slice (or greater) cardiac CT angiography (CTA) or clinically indicated coronary angiography.
|
24 months post CABG
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with at least 1 vein graft totally (100%) occluded.
Time Frame: 24 months post CABG
|
Proportion of patients who have at least 1 totally (100%) occluded vein graft at 24 months post CABG.
|
24 months post CABG
|
The percentage of vein grafts which are totally (100%) occluded grafts.
Time Frame: 24 months post CABG
|
Percentage of vein grafts that are totally (100%) occluded at 24 months post CABG.
|
24 months post CABG
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite rate of fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, cardiovascular death, coronary heart disease death, repeat coronary revascularization
Time Frame: 24 months post CABG
|
composite rate of occurrence of the above mentioned clinical outcomes at 24 months post CABG.
|
24 months post CABG
|
Rate of fatal and non-fatal myocardial infarction.
Time Frame: 24 months post CABG
|
Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.
|
24 months post CABG
|
Rate of fatal and non-fatal stroke.
Time Frame: 24 months post CABG
|
Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.
|
24 months post CABG
|
Rate of cardiovascular death.
Time Frame: 24 months post CABG
|
Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.
|
24 months post CABG
|
Rate of coronary heart disease death.
Time Frame: 24 months post CABG
|
Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.
|
24 months post CABG
|
Rate of repeat coronary revascularization.
Time Frame: 24 months post CABG
|
Rate of occurrence of the above mentioned clinical outcome at 24 months post CABG.
|
24 months post CABG
|
Rate of all-cause mortality.
Time Frame: 24 months post CABG
|
Proportion of patients who have died at 24 months post CABG.
|
24 months post CABG
|
Rate of total vein graft patency at 24 months.
Time Frame: 24 months post CABG
|
Rate of total vein graft patency defined as 1-VGDR at 24 months post CABG.
|
24 months post CABG
|
Percentage of patients free of vein graft disease at 24 months.
Time Frame: 24 months post CABG
|
Percentage of patients who are free of vein graft disease at 24 months defined as having no vein grafts with ≥ 50% stenosis.
|
24 months post CABG
|
Vein graft plaque volume.
Time Frame: 24 months post CABG
|
Volume of vein graft plaque at 24 months post CABG.
|
24 months post CABG
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Subodh Verma, MD, Unity Health Toronto
- Principal Investigator: David Mazer, MD, Unity Health Toronto
- Study Chair: Lawrence Leiter, MD, Unity Health Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEWTON CABG (Cardiolink-007)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States